


## Nilotinib

## Chemical Properties

CAS No. :	641571-10-0
Formula:	C <sub>28</sub> H <sub>22</sub> F <sub>3</sub> N <sub>7</sub> O
Molecular Weight:	529.52
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor with oral activity. Nilotinib has antitumor activity and may be used for the treatment of Imatinib-resistant chronic myelogenous leukemia (CML).
Targets(IC50)	Bcr-Abl, Autophagy
In vitro	<p><b>METHODS:</b> Ba/F3 cells expressing wild-type or mutant Bcr-Abl were treated with Nilotinib for 72 h, and cell viability was measured by methanethiosulfonate-based viability assay.</p> <p><b>RESULTS:</b> Nilotinib inhibited the growth of cells expressing wild-type Bcr-Abl with 20-fold higher potency than imatinib (IC<sub>50</sub>: 13 vs. 260 nmol/L). Similar improvements were maintained in all imatinib-resistant mutants tested except T315I. [1]</p> <p><b>METHODS:</b> Melanoma cell line D04 was treated with Nilotinib (0.1-10 μM) for 3 h. Target protein expression levels were examined by Western Blot.</p> <p><b>RESULTS:</b> Nilotinib stimulated robust MEK and ERK phosphorylation at concentrations as low as 100 nM. [2]</p>
In vivo	<p><b>METHODS:</b> To test the antitumor activity in vivo, Nilotinib (25 mg/kg) and PD184352 (25 mg/kg) were administered by gavage to Balb/cj mice bearing Ba/F3 allografts of BCR-ABL or BCR-ABL T315I once daily for twenty days.</p> <p><b>RESULTS:</b> Nilotinib strongly inhibited the growth of BCR-ABL tumors, but not PD184352, nor did PD184352 enhance the growth inhibitory activity of Nilotinib. In contrast, BCR-ABL T315I tumors were insensitive to both Nilotinib and PD184352, but these drugs synergistically inhibited tumor growth. [2]</p>
Kinase Assay	Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) were done as described, with minor alterations. GST-Abl fusion proteins were released from glutathione-Sepharose beads before use; the concentration of ATP was 5 μmol/L. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins were treated with LAR tyrosine phosphatase according to the manufacturer's instructions. After 1-hour incubation at 30°C, LAR phosphatase was inactivated by addition of sodium vanadate (1 mmol/L). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase was routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The inhibitor concentration ranges for IC <sub>50</sub> determinations

Kinase Assay	were 0 to 5,000 nmol/L (imatinib and AMN107) or 0 to 32 nmol/L (BMS-354825). The BMS-354825 concentration range was extended to 1,000 nmol/L for mutant T315I. These same inhibitor concentrations were used for the in vitro peptide substrate phosphorylation assays. The three inhibitors were tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase [1].
Cell Research	Ba/F3 cell lines were plated in triplicate and incubated with escalating concentrations of imatinib, AMN107, or BMS-354825 for 72 hours. Proliferation was measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges for IC50 and IC90 determinations were 0 to 2,000 nmol/L (imatinib and AMN107) or 0 to 32 nmol/L (BMS-354825). The imatinib concentration range was extended to 6,400 nmol/L for mutants with IC50 >2,000 nmol/L. The BMS-354825 concentration range was extended to 200 nmol/L for mutant T315I [1].
Animal Research	The GIST xenograft lines GK1X, GK2X and GK3X in nude mice were established from GIST patients as described in our previous study [10]. These xenograft lines were maintained by continual passage in BALB/cSLC-nu/nu mice. Mice bearing GK1X, GK2X and GK3X tumors (6-8 mice per group) were treated daily with vehicle or 40 mg/kg imatinib or nilotinib for 4 weeks. Tumor volume (TV) was determined from caliper measurements of tumor length (L) and width (w) according to the formula $LW^2/2$ . TV was determined every two to three days and on the day of evaluation. Mice were sacrificed and the percentage of tumor growth inhibition (TGI) was calculated as follows: $TGI (\%) = [1 - (\text{mean of treatment group tumor volume on evaluation day} - \text{mean of treatment group tumor volume on day 1}) / (\text{mean of control group tumor volume on evaluation day} - \text{mean of control group tumor volume on day 1})] \times 100$ [2].

### Solubility Information

Solubility	H2O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 41.7 mg/mL (78.75 mM), Sonication and heating are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.6 mg/mL (4.91 mM), Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8885 mL	9.4425 mL	18.885 mL
5 mM	0.3777 mL	1.8885 mL	3.777 mL
10 mM	0.1889 mL	0.9443 mL	1.8885 mL
50 mM	0.0378 mL	0.1889 mL	0.3777 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

- O'Hare T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Res.* 2005 Jun 1;65(11):4500-5.
- Cheng S, Jin P, Li H, et al. Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model. *Frontiers in Pharmacology.* 2021: 2866.
- Packer LM, et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. *Cancer Cell.* 2011 Dec 13;20(6):715-27.
- Kuang Y, Chai Y, Xu L, et al. Glabrone as a specific UGT1A9 probe substrate and its application in discovering the inhibitor glycycomarin. *European Journal of Pharmaceutical Sciences.* 2021: 105786.
- Sun R, Bao M Y, Long X, et al. Metabolic gene NR4A1 as a potential therapeutic target for non-smoking female non-small cell lung cancer patients. *Thoracic Cancer.* 2019 Apr;10(4):715-727
- Liu Y, et al. Inhibition of PDGF, TGF- $\beta$ , and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. *J Hepatol.* 2011 Sep;55(3):612-625.
- Rhee CK, et al. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. *Respiration.* 2011;82(3):273-87.
- Yan H, Wu W, Hu Y, et al. Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. *Nature Communications.* 2023, 14(1): 2756.
- Liu T, Yue X, Chen X, et al. Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma. *Cellular Oncology.* 2024: 1-18.
- Fujita KI, et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites. *J Pharm Sci.* 2017 Sep;106(9):2632-2641.
- Sun R, Bao M Y, Long X, et al. Metabolic gene NR4A1 as a potential therapeutic target for non-smoking female non-small cell lung cancer patients[J]. *Thoracic cancer.* 2019 Apr;10(4):715-727.
- Kuang Y, Chai Y, Xu L, et al. Glabrone as a specific UGT1A9 probe substrate and its application in discovering the inhibitor glycycomarin[J]. *European Journal of Pharmaceutical Sciences.* 2021: 105786.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481